Capital World Investors Trims Stock Position in Humana Inc. (NYSE:HUM)

Capital World Investors decreased its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 18.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,406,156 shares of the insurance provider's stock after selling 322,867 shares during the quarter. Capital World Investors owned about 1.17% of Humana worth $356,756,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of Humana during the third quarter worth approximately $631,000. Wilmington Savings Fund Society FSB purchased a new position in Humana in the third quarter valued at $948,000. Tidal Investments LLC grew its holdings in Humana by 38.4% in the third quarter. Tidal Investments LLC now owns 24,357 shares of the insurance provider's stock valued at $7,715,000 after purchasing an additional 6,755 shares during the period. Synovus Financial Corp lifted its stake in Humana by 4.1% in the 3rd quarter. Synovus Financial Corp now owns 2,254 shares of the insurance provider's stock valued at $714,000 after buying an additional 89 shares in the last quarter. Finally, Oddo BHF Asset Management Sas acquired a new stake in Humana during the 3rd quarter worth $1,306,000. Institutional investors own 92.38% of the company's stock.

Humana Stock Performance

Humana stock traded down $3.91 during midday trading on Friday, reaching $263.92. 1,097,937 shares of the company traded hands, compared to its average volume of 1,745,453. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The firm has a market capitalization of $31.85 billion, a price-to-earnings ratio of 26.52, a price-to-earnings-growth ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The business has a 50 day moving average of $266.22 and a two-hundred day moving average of $270.36.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. As a group, research analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. The ex-dividend date is Friday, June 27th. Humana's payout ratio is 35.58%.

Analyst Ratings Changes

A number of research analysts recently issued reports on HUM shares. Truist Financial lifted their price target on shares of Humana from $290.00 to $325.00 and gave the stock a "hold" rating in a research note on Friday, April 11th. Robert W. Baird lifted their price objective on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research report on Tuesday, April 15th. StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a research report on Monday, April 7th. Morgan Stanley reduced their price target on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 12th. Finally, Guggenheim assumed coverage on Humana in a research note on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price for the company. Seventeen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Humana currently has an average rating of "Hold" and a consensus target price of $284.90.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.